SK Pharmteco has finally completed its new Sejong plant, investing 260 million dollars (approximately 376 billion won) to strengthen its peptide production capacity, a key raw material in the rapidly growing obesity and diabetes treatment market.

The Sejong new plant is expected to serve as a strategic hub for SK Pharmteco to respond to the rapidly expanding peptide pharmaceutical market and strengthen its global contract development and manufacturing organization (CDMO) capabilities. The plant, to be operated by its subsidiary SK Biotech, is SK Pharmteco's fifth production facility established in Korea.

In 2024, SK Pharmteco announced that it would invest a total of 260 million dollars (approximately 376 billion won) in the construction of this plant with the goal of securing a leading position in the peptide pharmaceutical CDMO market. The completion of the Sejong new plant as of August 2, 2026 carries significant strategic importance in expanding domestic peptide production capacity and stabilizing the global supply chain.

[Photo=Yonhapnews]

The newly completed Sejong plant boasts a scale of approximately 12,600 square meters (about 3,800 pyeong). In particular, through 8 production trains, it has secured the capacity to produce tens of tons annually of high-quality peptides, and is equipped with state-of-the-art peptide research and development (R&D) facilities to pursue both production efficiency and technological innovation.

The new plant is scheduled to begin full-scale operations from 2027 and plans to focus on producing high-quality peptides essential for obesity and diabetes treatments. Recently in Korea, demand for GLP-1 class drugs such as 'Wegovy' and 'Mounjaro' has shown explosive growth. These peptide pharmaceuticals are transforming the paradigm of chronic disease treatment and emerging as a core growth driver in the global pharmaceutical market.

Through the full-scale operation of the Sejong new plant from 2027, SK Pharmteco is expected to further solidify its position in the global peptide CDMO market. It is anticipated that the company will play a crucial role in meeting the surging demand for obesity and diabetes treatments and establish itself as a leader in the world healthcare market.